Osteoporosis: Diagnosis, Prevention & Evidence-Based Treatment
Medically reviewed by Medical Advisory Board Last reviewed 2026-05-13
When bone density drops below the fracture threshold — causes, testing, and what actually works
Osteoporosis affects 10 million Americans and causes 2 million fractures annually. It is defined by a DEXA T-score below -2.5 and represents significant skeletal fragility. Early diagnosis and treatment can reduce fracture risk by 40-70%.
Osteoporosis is a skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, leading to increased bone fragility and fracture susceptibility. It is diagnosed when a DEXA scan reveals a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip — or when a fragility fracture occurs regardless of T-score.
The clinical significance of osteoporosis lies in its fractures. Hip fractures carry a 20-30% one-year mortality rate in adults over 65. Vertebral compression fractures cause chronic pain, height loss, and kyphosis. Wrist fractures, often the first osteoporotic fracture, are a warning signal for future hip and spine fractures.
Want expert help with your hormone health?
We can match you with a board-certified hormone specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →Despite effective treatments that reduce fracture risk by 40-70%, osteoporosis remains dramatically undertreated. Only 20-25% of women who sustain an osteoporotic fracture receive appropriate evaluation or treatment afterward.
Diagnosis and Risk Assessment
DEXA scan: Measures bone mineral density at the spine, hip, and sometimes forearm. T-score below -2.5 at any site confirms osteoporosis.
FRAX score: The WHO Fracture Risk Assessment Tool calculates 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors. Treatment is generally recommended when 10-year hip fracture risk exceeds 3% or major osteoporotic fracture risk exceeds 20%.
Secondary causes to evaluate: Vitamin D deficiency, hyperparathyroidism, hyperthyroidism, celiac disease, multiple myeloma, Cushing's syndrome, hypogonadism, and medication-induced bone loss (corticosteroids, aromatase inhibitors, anticonvulsants).
Treatment Options
First-line pharmacological therapy:
- Bisphosphonates (alendronate, risedronate, zoledronic acid): Reduce fracture risk by 40-50%. Work by inhibiting osteoclast-mediated bone resorption. Oral (weekly) or IV (yearly). Treatment duration: typically 5 years oral, 3 years IV, then reassess.
- Denosumab (Prolia): Monoclonal antibody targeting RANKL. Reduces hip fracture risk by 40%, vertebral by 68%. Given as subcutaneous injection every 6 months. Discontinuation causes rapid bone loss — transition plan required.
Anabolic agents (bone-building):
- Romosozumab (Evenity): Anti-sclerostin antibody that both builds bone and reduces resorption. Increases spine BMD by 13% and hip by 7% over 12 months. Reserved for very high fracture risk. 12-month treatment followed by antiresorptive therapy.
- Teriparatide (Forteo): PTH analog that stimulates osteoblasts. Increases spine BMD by 9-13% over 18-24 months. Maximum 2-year treatment course.
Lifestyle Interventions
- Exercise: Resistance training and weight-bearing impact exercise remain essential even with pharmacological treatment. Fall prevention (balance training, tai chi) reduces fracture risk by preventing falls, which is equally important as improving bone density.
- Nutrition: Calcium 1,200 mg/day, vitamin D to maintain 25(OH)D above 40 ng/mL, protein 1.0-1.2 g/kg/day. Vitamin K2 (MK-7, 100-200 mcg/day) may improve calcium deposition into bone rather than soft tissues.
- Fall prevention: Home safety assessment (rugs, lighting, grab bars), vision correction, medication review (sedatives, antihypertensives that cause dizziness), and balance exercises reduce fall risk by 30-40%.
Practical guides: DEXA scan and diagnosis, T-score and Z-score, bone-building exercise, calcium-rich foods, earlier-stage osteopenia, and menopause-related bone loss.
Frequently Asked Questions
Can osteoporosis be reversed?
Osteoporosis can be significantly improved with modern treatments. Anabolic agents like romosozumab can increase spine bone density by 13% in 12 months, and teriparatide by 9-13% over 2 years. Bisphosphonates and denosumab prevent further loss and modestly increase density. While complete reversal to normal T-scores is uncommon, reducing fracture risk by 40-70% with treatment is well established.
What are the 3 worst bone density drugs?
This question typically refers to concerns about bisphosphonate side effects. The rare but serious risks include: (1) atypical femur fractures (risk: ~1 in 10,000 per year, mainly with use beyond 5 years), (2) osteonecrosis of the jaw (risk: ~1 in 10,000-100,000 for oral bisphosphonates, higher with IV formulations in cancer patients), and (3) esophageal irritation with oral bisphosphonates. However, for most patients the fracture-prevention benefit far outweighs these risks. Drug holidays after 5 years of oral or 3 years of IV bisphosphonates mitigate long-term risks.
Can osteoporosis be reversed to osteopenia?
Yes, this is achievable with treatment. Anabolic agents (romosozumab, teriparatide) can increase bone density enough to shift T-scores from the osteoporosis range into osteopenia. Even antiresorptive treatments (bisphosphonates, denosumab) can achieve this, particularly at the lumbar spine. The goal of treatment is primarily fracture prevention, but T-score improvement is a measurable outcome.
How to prevent osteoporosis after menopause?
Prevention starts during the accelerated bone loss phase (first 5-7 years postmenopause): (1) progressive resistance training 2-3x/week with impact exercises, (2) calcium 1,200 mg/day from food + supplements, (3) vitamin D 1,000-4,000 IU/day to maintain levels above 40 ng/mL, (4) adequate protein, (5) consider hormone therapy if appropriate (reduces fracture risk 30-40%), and (6) baseline DEXA scan within 2 years of menopause if risk factors are present.
Topic updates
Get the weekly hormone optimization roundup
Testosterone, thyroid, cortisol, estrogen, menopause, perimenopause, libido, and hormone testing.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
← Back to Hormone Optimization
-
Menopause, fatigue, weight gain, and metabolic health
Menopause symptoms, body composition, testing, and treatment paths.
-
Perimenopause symptoms, fatigue, and early hormone changes
Early-transition fatigue, weight gain, sleep disruption, and symptom triage.
-
Low testosterone in men: symptoms, causes, and treatment
Symptoms, causes, and treatment options for low T in men.
-
Hormone imbalance: symptoms, causes, and how to fix it
How hormonal imbalances present differently in men and women.
-
Thyroid symptoms: hypothyroidism vs hyperthyroidism and what your labs mean
Hypothyroidism vs hyperthyroidism — symptoms and what labs reveal.
-
High cortisol symptoms: signs your stress hormones are too high
Chronic stress signs: weight gain, insomnia, anxiety, impaired recovery.
-
Perimenopause symptoms: the complete guide
The complete symptom list — hot flashes affect ~80% of women.
-
Perimenopause fatigue: causes and energy solutions
Why perimenopause causes fatigue and what to do about it.
-
Brain fog: hormonal causes and how to clear it
Hormonal causes of cognitive sluggishness — thyroid, cortisol, estrogen.
-
What causes low testosterone? Root causes explained
Root causes: age, obesity, sleep, medications, chronic illness.